Phase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With Advanced Renal Cancer

NCT00142415 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Renal Cell Carcinoma

Interventions

DRUG: 111-In-DOTA-cG250
DRUG: 177-Lu-DOTA-cG250

Sponsor

Ludwig Institute for Cancer Research

Collaborators

[object Object]